BASF and Poietis sign 3D bioprinting technology agreement

By Simon Pitman

- Last updated on GMT

BASF and Poietis sign 3D bioprinting technology agreement

Related tags Skin Cosmetics BASF

BASF has expanded its footprint in the expanding areas of 3D bioprinting, a move that is expected to further increase its offerings in this area to the cosmetics and personal care industry.

Two years after concluding a research and deveoplment agreement in this area, BASF and Poietis have announced the signing of a framework agreement on further development and services in 3D bioprinting technology.

The agreement will enable BASF to improve its existing 3D laser-assisted skin models, which have been developed since 2015 as a means of evaluating cosmetic ingredients for the skin care category.

Fulfilling strict regulations to avoid animal testing

The implementation of REACH in Europe meant that the testing of skin care ingredients and formulations on animals was completely outlawed, leading to the need for skin replication.

The 3D laser-assisted bioprinting technology means that organic skin tissues can be reproduced, allowing a precise positioning of skin cells in three-dimensional structures, the researcher teams claim.

“Bio-printed 3D models are the method of choice for the predictive evaluation of ingredients as these models reproduce the cell environment in vitro by having mechanical and metabolic functionalities close to the vivo”,​ explained Fabien Guillemot, Founder and President of Poietis.

Obtaining the optimal bioprinted epedermis

The development teams from both companies say that they have gained significant insights into the parameters and kinetics of dermis maturation, enabling them to obtain an optimally mature and thick dermis for the epidermal printing – a model that is as close to human skin as possible.

In the coming years, BASF says that it intends to develop and market several active ingredients for cosmetic products that harness the findings of the collaboration.

“This agreement confirms a fruitful scientific collaboration and strengthens our partnership with the leading ingredients manufacturer for the personal care market. This is a formal recognition of Poietis' unique technology and its valorization driven by new developments since the creation of the company”,​ said Bruno Brisson, Poietis Co-Founder and Vice President Business Development.

Related news

Related products

show more

Calendula Cellular Elixir: Alchemy in a cell

Calendula Cellular Elixir: Alchemy in a cell

Content provided by Naolys | 24-Apr-2024 | Product Brochure

Get ready to experience a cellular evolution in skincare with InnerLift Calendula's advanced Plant Cell biotechnology.

See our latest innovations in personal care

See our latest innovations in personal care

Content provided by Covation Bio™ PDO | 02-Apr-2024 | White Paper

At CovationBio PDO, we’re helping the world achieve its sustainability goals by enabling better performing, better-for-the planet products across a range...

Collagen Reimagined, Discover Biodesigned Type XXI

Collagen Reimagined, Discover Biodesigned Type XXI

Content provided by Geltor | 20-Mar-2024 | Product Brochure

Collagen is the body’s most abundant protein and a mainstream ingredient for beauty. Type XXI collagen transcends a common protein into a powerful bioactive

Empowering natural barrier function for future-proof skin

Empowering natural barrier function for future-proof skin

Content provided by Lucas Meyer Cosmetics | 14-Mar-2024 | White Paper

Corneopeptyl™ is a new patented peptide biomimetic to the LCE6A protein, obtained by green chemistry-based synthesis. By mimicking the LCE6A protein activity,...

Related suppliers

Follow us


View more



Beauty 4.0 Podcast